Remarkably, aramchol enhanced sensitivity of p53 wild-type cancer cells to donafenib, a deuterated sorafenib derivative7 showed superiority over sorafenib, in long-term clonogenic assays (Fig. 6b, c). This evidence concerns the gene TP53 and cancer.